While this option may be less expensive and seems convenient, it’s best to consult a doctor about dosage if you use it, says Joshua J. Neumiller, CDCES, PharmD, the president elect of ...

Diabetes mellitus is a metabolic disease that causes high blood sugar. Your body either doesn’t make enough insulin or can’t effectively use the insulin it makes. The hormone insulin moves ...

Polycystic ovary syndrome (PCOS) can put you at risk for insulin resistance. Watch for symptoms of insulin resistance that are common for females with PCOS. These include cravings and frequent ...

A single-center pilot study at the Veterans Affairs Hospital/University of Washington in Seattle reported improved verbal memory retention and attention after a three-week test of 20 international ...

Once there, he received 10 vials of antivenom, however, the swelling on his shin continued to increase. At first, the pain was so bad that he didn’t think it was the result of a snake bite.

A total of 94 patients were eligible for study inclusion and randomization from July 2005 through May 2006; 45 were randomized to the vial and syringe group and 49 were randomized to the insulin ...

Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that ...

The action was brought on behalf of Jaime Vial and other heirs of a Chilean man who owned stocks in companies incorporated in Delaware such as Citigroup Inc. and Hilton Hotels Corp. The Office of ...

This has enabled the local formulation, filling and finishing of insulin vials and cartridges. In parallel, EVA has submitted its insulin injection for local regulatory approval. The collaboration ...

The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly (LLY). Launched in 2022, the collaboration aims to deliver a ...

fill and finish insulin vials and cartridges. Less than two years after the initial announcement, EVA Pharma has completed a new biologics manufacturing facility, finalized insulin formulations ...

The list prices of its insulin drug Fiasp will be reduced by 75%, while the list prices of its Tresiba insulin will be reduced by 72.2%, Novo said in a statement. As a result, Novo will discontinue ...